Patents by Inventor Isaac Marx

Isaac Marx has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961237
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: March 30, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Patent number: 10899753
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 26, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Jürgen Schulz, Marta Nevalainen, Michael Dechantsreiter
  • Publication number: 20200239459
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: August 7, 2019
    Publication date: July 30, 2020
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Publication number: 20190382394
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: May 13, 2019
    Publication date: December 19, 2019
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Jürgen Schulz, Marta Nevalainen, Michael Dechantsreiter
  • Patent number: 10227341
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: March 12, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos
  • Patent number: 10189829
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 29, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Publication number: 20180362522
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Publication number: 20180297992
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Publication number: 20140336182
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    Type: Application
    Filed: May 13, 2013
    Publication date: November 13, 2014
    Inventors: Victor J. CEE, Holly L. DEAK, Bingfan DU, Stephanie D. GEUNS-MEYER, Zihao HUA, Matthew W. MARTIN, Isaac MARX, Hanh Nho NGUYEN, Philip R. OLIVIERI, Kathleen PANTER FABER, Karina ROMERO, Laurie SCHENKEL, Ryan WHITE
  • Patent number: 8883782
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: November 11, 2014
    Assignee: Amgen Inc.
    Inventors: Yuan Cheng, Ryan White, Albert Amegadzie, James Brown, Alan C. Cheng, Erin F. Dimauro, Thomas Dineen, Oleg Epstein, Vijay Keshav Gore, Jason Brooks Human, Ted Judd, Charles Kreiman, Qingyian Liu, Patricia Lopez, Vu Van Ma, Isaac Marx, Ana Minatti, Hanh Nho Nguyen, Nick A. Paras, Vinod F. Patel, Wenyuan Qian, Matthew Weiss, Qiufen Xue, Xiao Mei Zheng, Wenge Zhong
  • Patent number: 8557816
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: October 15, 2013
    Assignee: Amgen Inc.
    Inventors: Stephanie Geuns-Meyer, Victor J. Cee, Isaac Marx, Laurie Schenkel, Ryan White
  • Patent number: 8426447
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: April 23, 2013
    Assignee: Amgen Inc.
    Inventors: Ryan White, Albert Amegadzie, Marian C. Bryan, Jian Jeffrey Chen, Alan C. Cheng, Thomas Dineen, Oleg Epstein, Vijay Keshav Gore, Zihao Hua, Jason Brooks Human, Hongbing Huang, Charles Kreiman, Daniel La, Qingyian Liu, Vu Van Ma, Isaac Marx, Vinod F Patel, Wenyuan Qian, Matthew Weiss, Chester Chenguang Yuan
  • Publication number: 20110301162
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinase proteins. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds and methods of treating disease states related to the activity of Aurora kinase.
    Type: Application
    Filed: August 4, 2009
    Publication date: December 8, 2011
    Applicant: AMGEN INC.
    Inventors: Holly L. Deak, Stephanie D. Geuns-Meyer, Jason Brooks Human, Matthew W. Martin, Isaac Marx
  • Publication number: 20110251186
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: March 14, 2011
    Publication date: October 13, 2011
    Applicant: Amgen Inc.
    Inventors: Jian J. CHEN, Wenge ZHONG, Bryant YANG, Wenyuan QIAN, Patricia LOPEZ, Ryan WHITE, Matthew WEISS, Ted JUDD, Timothy POWERS, Yuan CHENG, Thomas DINEEN, Oleg EPSTEIN, Jonathan LOW, Isaac MARX, Ana Elena MINATTI, Michele POTASHMAN, Nick A. PARAS
  • Publication number: 20110251190
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: March 14, 2011
    Publication date: October 13, 2011
    Applicant: Amgen Inc.
    Inventors: Yuan CHENG, Ryan White, Albert Amegadzie, James Brown, Alan C. Cheng, Erin F. Dimauro, Thomas Dineen, Oleg Epstein, Vijay Keshav Gore, Jason Brooks Human, Ted Judd, Charles Kreiman, Qingyian Liu, Patricia Lopez, Vu Van Ma, Isaac Marx, Ana Minatti, Hanh Nho Nguyen, Nick A. Paras, Vinod F. Patel, Wenyuan Qian, Matthew Weiss, Qiufen Xue, Xiao Mei Zheng, Wenge Zhong
  • Patent number: 7776857
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: August 17, 2010
    Assignee: Amgen Inc.
    Inventors: Victor Cee, Holly Deak, Bingfan Du, Stephanie Geuns-Meyer, Brian L. Hodous, Zihao Hua, Matthew Martin, Isaac Marx, Hanh Nho Nguyen, Philip Olivieri, Kathleen Panter, Karina Romero, Laurie Schenkel, Ryan White
  • Publication number: 20100087429
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: September 11, 2009
    Publication date: April 8, 2010
    Applicant: Amgen Inc.
    Inventors: Ryan White, Albert Amegadzie, Marian C. Bryan, Jian Jeffrey Chen, Alan C. Cheng, Thomas Dineen, Oleg Epstein, Vijay Keshav Gore, Zihao Hua, Jason Brooks Human, Hongbing Huang, Charles Kreiman, Daniel La, Qingyian Liu, Vu Van Ma, Isaac Marx, Vinod F. Patel, Wenyuan Qian, Matthew Weiss, Chester Chenguang Yuan
  • Publication number: 20090069297
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    Type: Application
    Filed: April 3, 2008
    Publication date: March 12, 2009
    Applicant: Amgen Inc.
    Inventors: Victor Cee, Holly Deak, Bingfan Du, Stephanie Geuns-Meyer, Brian L. Hodous, Zihao Hua, Mathew Martin, Isaac Marx, Hanh Nho Nguyen, Philip Olivieri, Kathleen Panter, Karina Romero, Laurie Schenkel, Ryan White